Nothing Special   »   [go: up one dir, main page]

NO20025811L - Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer - Google Patents

Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer

Info

Publication number
NO20025811L
NO20025811L NO20025811A NO20025811A NO20025811L NO 20025811 L NO20025811 L NO 20025811L NO 20025811 A NO20025811 A NO 20025811A NO 20025811 A NO20025811 A NO 20025811A NO 20025811 L NO20025811 L NO 20025811L
Authority
NO
Norway
Prior art keywords
beta
well
pde4 inhibitors
adrenoceptor agonists
compounds effective
Prior art date
Application number
NO20025811A
Other languages
English (en)
Other versions
NO20025811D0 (no
Inventor
Armin Hatzelmann
Daniela Bundschuh
Manfrid Eltze
Geert Jan Sterk
Yvonne Johanna Van Der Laan
Hendrik Timmermann
Johannes A M Christiaans
Paulus Johannes Gaurer Brundel
Original Assignee
Altana Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Bv filed Critical Altana Pharma Bv
Publication of NO20025811D0 publication Critical patent/NO20025811D0/no
Publication of NO20025811L publication Critical patent/NO20025811L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelsene med formel I. i hvilke Ari, A, R6, R7, R8, og Arhar betydningene som er angitt i beskrivelsen, er nye effektive bronkialterapeutika.
NO20025811A 2000-06-05 2002-12-03 Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer NO20025811L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00111795 2000-06-05
PCT/EP2001/006230 WO2001094319A1 (en) 2000-06-05 2001-06-01 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors

Publications (2)

Publication Number Publication Date
NO20025811D0 NO20025811D0 (no) 2002-12-03
NO20025811L true NO20025811L (no) 2003-02-04

Family

ID=8168897

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025811A NO20025811L (no) 2000-06-05 2002-12-03 Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer

Country Status (20)

Country Link
US (1) US6933296B2 (no)
EP (1) EP1296956A1 (no)
JP (1) JP2003535850A (no)
KR (1) KR20030031907A (no)
CN (1) CN1471515A (no)
AU (2) AU6233201A (no)
BR (1) BR0111440A (no)
CA (1) CA2411351A1 (no)
CZ (1) CZ20023997A3 (no)
EA (1) EA005824B1 (no)
HK (1) HK1052346A1 (no)
HU (1) HUP0301240A3 (no)
IL (1) IL152846A0 (no)
MX (1) MXPA02012042A (no)
NO (1) NO20025811L (no)
NZ (1) NZ522882A (no)
PL (1) PL358057A1 (no)
SK (1) SK17052002A3 (no)
WO (1) WO2001094319A1 (no)
ZA (1) ZA200209598B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362044A1 (en) 2001-02-15 2003-11-19 ALTANA Pharma AG Phthalazinone-piperidino-derivatives as pde4 inhibitors
US7022696B2 (en) 2001-04-25 2006-04-04 Altana Pharma Ag Piperazino-derivatives and their use as PDE4 inhibitor
EP1385848A2 (en) 2001-04-25 2004-02-04 ALTANA Pharma AG Phtalazinones derivatives useful as pde4/7 inhibitors
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PL373146A1 (en) * 2002-08-10 2005-08-22 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
JP4555684B2 (ja) * 2002-08-10 2010-10-06 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤としての、ピロリジンジオンにより置換されたピペリジン−フタラゾン
PL373597A1 (en) * 2002-08-10 2005-09-05 Altana Pharma Ag Piperidine-n-oxide-derivatives
JP2006513222A (ja) * 2002-12-23 2006-04-20 アルテシアン セラピューティック，インコーポレイティド アドレナリン性β受容体およびホスホジエステラーゼに対する抑制活性を有する強心性化合物
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1716123A1 (en) * 2004-02-04 2006-11-02 Altana Pharma AG Pyridazinone derivatives and their use as pde4 inhibitors
EP1716133B1 (en) * 2004-02-04 2008-03-26 Nycomed GmbH 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
MX2008006076A (es) 2005-11-09 2008-12-16 Combinatorx Inc Metodos, composiciones y kits para el tratamiento de condiciones medicas.
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
GB0805535D0 (en) 2008-03-27 2008-04-30 Univ Leicester Scar prevention
JP5529131B2 (ja) * 2008-08-13 2014-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング キマーゼ阻害薬
CA2796826A1 (en) * 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
AR081377A1 (es) 2010-05-10 2012-08-29 Gilead Sciences Inc Compuestos de pirazolopiridina bifuncionales
CA2837248A1 (en) * 2011-06-17 2012-12-20 Takeda Gmbh Novel phthalazinone -pyrrolopyrimidinecarboxamide derivatives
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
GB2513297A (en) 2013-03-08 2014-10-29 Univ Leicester Methods
FI3877376T3 (fi) 2018-11-06 2023-09-26 Edgewise Therapeutics Inc Pyridatsinoniyhdisteitä ja niiden käyttöjä
CA3118904A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
WO2021231572A1 (en) * 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030835B1 (en) 1979-12-05 1983-05-11 Morishita Pharmaceutical Co. Ltd. Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
JPS58146571A (ja) 1982-02-25 1983-09-01 Morishita Seiyaku Kk ウレア誘導体およびその製造法
PL164079B1 (pl) * 1990-06-15 1994-06-30 Akad Medyczna posób wytwarzania nowych 2-amlnoalkilopochodnych 5-aminometyleno-6-/p-chlorofenylo /-4,5-dihydro-2H- plrydazyn -3-onu
ATE234270T1 (de) 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
US6103718A (en) * 1997-01-15 2000-08-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinones
ES2302350T3 (es) 1997-02-28 2008-07-01 Nycomed Gmbh Combinacion sinergica de inhibidores de pde y agonistas de adenilatociclasa o agonistas de guanililciclasa.
WO1999031071A1 (en) * 1997-12-15 1999-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
US6380196B1 (en) * 1997-12-15 2002-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurans
EP0934933A1 (en) * 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
CN1314811A (zh) 1998-08-26 2001-09-26 史密丝克莱恩比彻姆公司 治疗肺病的方法

Also Published As

Publication number Publication date
US20030195215A1 (en) 2003-10-16
AU2001262332B2 (en) 2006-05-25
BR0111440A (pt) 2003-06-03
NO20025811D0 (no) 2002-12-03
IL152846A0 (en) 2003-06-24
CZ20023997A3 (cs) 2003-05-14
HUP0301240A2 (hu) 2003-12-29
CA2411351A1 (en) 2001-12-13
NZ522882A (en) 2004-07-30
ZA200209598B (en) 2003-07-29
SK17052002A3 (sk) 2003-12-02
US6933296B2 (en) 2005-08-23
WO2001094319A1 (en) 2001-12-13
EA005824B1 (ru) 2005-06-30
EA200201252A1 (ru) 2003-06-26
PL358057A1 (en) 2004-08-09
HK1052346A1 (zh) 2003-09-11
MXPA02012042A (es) 2004-08-19
KR20030031907A (ko) 2003-04-23
CN1471515A (zh) 2004-01-28
EP1296956A1 (en) 2003-04-02
JP2003535850A (ja) 2003-12-02
AU6233201A (en) 2001-12-17
HUP0301240A3 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
NO20025811L (no) Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
BRPI0608886B8 (pt) derivados de n-sulfonilpirróis e seus usos
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20064415L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
NO20051082L (no) Antimikrobielle kinoloner, deres sammensetninger og anvendelser
DE60334536D1 (de) Furylverbindungen
ATE477256T1 (de) Thienylverbindungen
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
NO20064491L (no) Nye difluomtoksysubstituee hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
ATE308325T1 (de) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
NO20064417L (no) Nye isoamidosubstituertehydroksy-6-fenylfenantridiner
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
NO20015892D0 (no) Inhibitorer av metallproteinaser
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
ATE293111T1 (de) Kondensierte pyrazindionderivate als pde inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application